ProBioGen announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for proteins as well as the completion of the construction phase of its virus manufacturing unit.

In the protein vertical, this strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development through to commercial manufacturing. Utilizing its CHO.RiGHT® platform in combination with market-approved technologies such as the DirectedLuck® transposase and the ADCC enhancement GlymaxX®, ProBioGen reinforces its position as a reliable partner in the industry. With this investment the company strengthens its footprint in the market and is advancing its state-of-the-art facilities across two manufacturing sites.

In the viral vector arena, ProBioGen is building on a broad experience in developing proprietary viral manufacturing platforms to offer solutions that go beyond standard processes. The company provides tailored cell lines for producing viral vectors and virus-like particles (VLPs). This includes customized stable cell line development for lentiviral (LV) and adeno-associated virus (AAV) production, addressing the unique challenges of emerging therapeutic platforms and enabling the creation of next-generation therapies with precision and efficiency.

"These strategic initiatives mark a major milestone for us as we continue to grow and better fulfill our customer's needs", explained Dr. Alfred Merz, Chief Executive Officer at ProBioGen.